On May 22, 3:05*pm, ironjustice <ironjust...@cashette.com> wrote:
JUVENILE RHEUMATOID ARTHRITIS <<
Rheumatoid factor (RF)
This is evidence of erythrocytosis / increased red blood cell
production .
Rheumatoid factor (RF) rises as one goes to altitude.
The higher you go the higher your RF and the higher your red blood
cell count / erythrocytosis.
http://www.labtestsonline.org.au/und...tions/jra.html
Rheumatoid factor (RF) – may be positive or negative depending on the
type of JRA;
Am J Med Sci. 2003 Sep;326(3):148-51. Related Articles, Links
Successful treatment with cyclosporin in adult-onset still disease
manifesting
as acute hepatitis with marked hyperferritinemia.
Omagari K, Matsunaga Y, Yamashita H, Nishiyama H, Hazama H, Oda H,
Isomoto H,
Mizuta Y, Murase K, Kohno S.
SUMMARY: ABSTRACT A 48-year-old woman was admitted because of spiking
high
fever, sore throat, and jaundice. A diagnosis was made of adult-onset
Still
disease (AOSD) presenting with acute hepatitis and very high serum
ferritin
levels (32,240 ng/mL), and she was treated with 2 courses of pulse
therapy of
methylprednisolone (2 g/day for 3 days) followed by 40 mg/day
prednisolone.
Subsequently, the serum level of ferritin decreased, but serum total
bilirubin
increased to 17.3 mg/dL. Therefore, cyclosporin was administered
orally. Within
the next 3 months, results of liver function tests, as well as serum
levels of
ferritin, soluble interleukin-2 receptor, interferon-gamma,
interleukin-6, and
tumor necrosis factor-alpha gradually returned to within normal
limits, and
cyclosporin administration was subsequently reduced gradually. The
clinical
presentation suggests that AOSD should be considered when liver
dysfunction is
accompanied with high fever and extreme hyperferritinemia, and that
treatment
with cyclosporin or other immunosuppressive drugs that selectively
suppress
cytokine production by helper T cells is a valuable option in the
treatment of
AOSD with very high serum ferritin levels.
PMID: 14501232 [PubMed - in process]
--------------------------------------------------------------------------
Now WHY .. in these three DIFFERENT diseases .. does the drop of iron
.. PARALLEL .. the drop in alanine aminotransferase (ALT) .. but in
the
disease of .. juvenile rheumatoid arthritis / Still's .. do they
NOT ..
use this marker .. WHEN .. iron HAS been shown to BE a ..
problem .. ?
Especially .. when they have such high liver injury rates. Two
thirds.
Stupidity .. ?
<<snip>>
There was a positive correlation between transaminases and serum
ferritin
<<snip>>
J Nephrol. 2003 Sep-Oct; 16(5): 703-9. Related Articles, Links
Comparative study of intravenous ascorbic acid versus low-dose
desferroxamine
in patients on hemodialysis with hyperferritinemia.
Deira J, Diego J, Martinez R, Oyarbide A, Gonzalez A, Diaz H, Grande
J.
Department of Internal Medicine, Division of Nephrology, Hospital
Virgen de la
Concha, Zamora, Spain. jde...@saludalia.com
BACKGROUND: In patients on hemodialysis (HD), parenteral iron
improves
the
response to recombinant human erythropoietin (rhuEPO) therapy, but in
some
subjects it produces an iron overload, increasing their morbidity and
mortality
rates. In these cases, iron administration must be discontinued. This
study
aimed to investigate the efficiency of treatment with ascorbic acid
(AA) or
desferroxamine (DFO) to mobilize and reduce iron stores, and to
determine the
effect of these compounds on erythropoiesis. METHODS: We performed a
prospective and randomized trial over 6 months, which included 27
patients with
serum ferritin levels >800 ng/mL, TSAT >30% and stabilized hemoglobin
(Hb) and
rhuEPO doses. All patients had previously received parenteral iron
(Ferlecit).
Nine patients received 200 mg of intravenous (i.v.) AA 3 times/week
and
nine
patients received 1 mg/Kg/week of DFO; the remaining nine patients
were
the
control group. RESULTS: There were no significant differences in iron
loss or
mobilization due to dialysis. When Ferlecit was discontinued,
functional iron
did not vary and the epoetin resistance index (rhuEPO dose/Hb) was
reduced by
21% in the i.v. AA group. In the DFO and control groups, functional
iron levels
fell. In the DFO group the epoetin resistance index increased by 20%,
with no
modifications in the control group. There was a positive correlation
between
transaminases and serum ferritin. CONCLUSIONS: In HD patients with an
iron
overload, neither i.v. AA administration or low-dose DFO increased
iron
mobilization or iron loss due to dialysis. I.v. AA administration
allows
elimination of iron from stores without any drop in the functional
iron
produced by discontinuing parenteral maintenance iron; it also
improves
the
response to rhuEPO. DFO did not elicit any positive effects on
erythropoiesis.
PMID: 14733417 [PubMed - in process]
--------------------------------------------------------------------------
------
<<snip>>
The treatment reduced mean serum alanine aminotransferase (ALT)
activity
<<snip>>
Effect of iron reduction by phlebotomy in Japanese patients with
nonalcoholic steatohepatitis: A pilot study.
Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K, Nakashima T,
Okanoue T
Hepatol Res. 2006 Sep 11;
Increased hepatic iron deposition may play a role in the pathogenesis
of nonalcoholic steatohepatitis (NASH). This study aimed to test
whether iron removal by phlebotomy improves serum transaminase
activities in patients with NASH. Eleven patients (six males and five
females) with biopsy-proven NASH underwent phlebotomy biweekly until
they reached near-iron deficiency (NID) (serum ferritin concentration
lower than or equal to 30ng/ml). Nine patients completed this study.
Serum ferritin levels in these patients fell from 563+/-322 to
18+/-9ng/ml (p=0.001). The treatment reduced mean serum alanine
aminotransferase (ALT) activity from 126+/-47 to 56+/-17IU/l
(p=0.002).
Their weight did not change significantly throughout the study
period.
Although two patients withdrew from the study, none was affected by
any
side effects of repeated phlebotomy that required discontinuing the
treatment. In conclusion, this pilot study suggests that iron
reduction
therapy by phlebotomy will be one of the promising therapies for
NASH.
---------------------------------------------------------------------------
<<snip>>
Serum alanine aminotransferase levels were significantly improved
<<snip>>
Hepatogastroenterology. 2005 Mar-Apr;52(62):563-6. Related Articles,
Links
Additional effect of low iron diet on iron reduction therapy by
phlebotomy for chronic hepatitis C.
Kimura F, Hayashi H, Yano M, Yoshioka K, Matsumura T, Fukuda T,
Shigeto
N, Yamahara S, Koushi F, Mishima Y, Yoshino T, Tanimoto M, Kimura I.
Department of Internal Medicine, Tamano-Municipal Hospital, Tamano
City, Okayama, Japan. f-kim...@po1.oninet.ne.jp
BACKGROUND/AIMS: Iron-induced oxidative stress plays an important
role
in the pathogenesis of chronic hepatitis C. Both phlebotomy for
removing body iron stores and low iron diet for minimizing portal
iron
supply to the liver have been shown to improve serum transaminase
levels in patients with the disease. However, the cooperative effects
of phlebotomy and low iron diet have not yet been elucidated in
detail.
METHODOLOGY: A pilot study was undertaken to investigate whether a
low
iron diet could improve the efficacy of phlebotomy in iron reduction
therapy. Of 21 patients diagnosed with chronic hepatitis C, 10
patients
were treated with phlebotomy alone (group A) while 11 patients were
treated with a low iron plus phlebotomy (group B). Phlebotomy was
repeated biweekly until serum ferritin levels reached 10 ng/mL in
both
A and B groups. In addition, a low iron diet (iron intake of 8 mg/day
or less) was recommended for group B, followed by estimation of iron
intake from daily diet records.
RESULTS: Serum alanine aminotransferase
levels were significantly improved from 106+/-30 to 68+/-22 IU/L
(p<0.005, paired t-test) in group A and from 100+/-33 to 46+/-10 IU/L
(p<0.002, paired t-test) in group B. The enzyme levels after
treatment
were significantly higher in group A (p<0.02, non-paired t-test),
which
showed a higher upward distribution of the enzyme activity. The
estimated dietary iron intake in group B was reduced from 17.6+/-6.1
to
8.2+/-3.7 mg/day.
CONCLUSIONS: These findings suggest that phlebotomy
alone does not completely remove iron-induced oxidative stress and a
low iron diet induces an additional effect in iron reduction therapy
for chronic hepatitis C.
PMID: 15816478 [PubMed - in process]
---------------------------------------------------------------------------
Who loves ya.
Tom
Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh
Man Is A Herbivore!
http://tinyurl.com/a3cc3
DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk
> On May 22, 2:54*pm, ironjustice <ironjust...@cashette.com> wrote:They
> give you iron and you die <<
>
> I suppose die .. screaming .. would be more appropriate.
>
> IRON DEPOSITION IN THE JOINTS OF CHILDREN WITH JUVENILE RHEUMATOID
> ARTHRITIS
>
> * *Author(s):
> * * * * * SHYPAILO ROMAN J
> * * * * * ELLIS KENNETH J
> * * * * * PEREZ MARIA
> * * * * * ABRAMS STEVEN A
>
> * *Interpretive Summary:
> * * * * * We wanted to develop an accurate and noninvasive way of
> * * * * * determining the amount of iron deposited in the jointsof
> * * * * * patients with juvenile rheumatoid arthritis. Children with
> JRA
> * * * * * often develop excess iron in their joints, so doctors need
> a
> * * * * * way of monitoring the iron level, particularly when
> prescribing
> * * * * * iron supplements for the common problem of anemia. However,
> the
> * * * * * only method currently available is to take a biopsy. We
> adapted
> * * * * * a machine called a gamma counter to measure the iron in
> eight
> * * * * * patients' joints after giving them an iron isotope by vein.
> * * * * * Then we compared the results with the total amount of iron
> in
> * * * * * their bodies, measured by a whole-body counter. We found
> that
> * * * * * we had developed an accurate new way of measuring ironin
> these
> * * * * * patients' joints. We also found that six of the eight
> subjects
> * * * * * had excess uptake of the iron isotope in their joints.That
> * * * * * provided a signal that a preponderance of JRA patientsare
> * * * * * prone to have this problem, and clinicians should take
> special
> * * * * * care to monitor them for it. Moreover, this is the first
> time a
> * * * * * noninvasive way of performing this measurement has been
> * * * * * available.
>
> * *Keywords:
> * * * * * energy reproduction growth body composition women infants
> * * * * * children water potassium bioelectrical impedance
> conductance
> * * * * * bromide space lactating iron adipose tissue lipid
> motabolism
> * * * * * beta-adrenergic receptor cell culture neutron activation
> * * * * * nitrogen carbon calcium sodium chlorine phosphorus hormonal
> * * * * * changes differentiation adipocyte hnrim021125
>
> * *Contact:
> * * * * * USDA/ARS CHILDREN'S NUTR
> * * * * * 1100 BATES ST.
> * * * * * HOUSTON
> * * * * * TX 77030
> * * * * * FAX: (713)798-7130
> * * * * * Email: kel...@bcm.tmc.edu
>
> * *Approved Date: 1999-01-07
>
> __________________________________________________ ____________________
>
> * * TEKTRAN
> * * United States Department of Agriculture
> * * Agricultural Research Service
>
> * *Updated: 1999-01-16
>
> ----------------------------------------
>
> * *Title: Mechanism of exacerbation of rheumatoid synovitis by total-
> dose
> * *iron-dextran infusion: in-vivo demonstration of iron-promoted
> oxidant
> * *stress.
>
> * *Author(s): Winyard PG; Blake DR; Chirico S; Gutteridge JM; Lunec J
>
> * *Source: Lancet 1987 Jan 10;1(8524):69-72
>
> * *Abstract: The mechanism by which a synovial flare occurred in a
> * *patient with rheumatoid arthritis after intravenous infusion of
> * *iron-dextran was investigated. After the infusion, serum and
> * *synovial-fluid iron-binding capacity became saturated, giving rise
> to
> * *low-molecular-mass iron chelates with the capacity to cause
> oxidative
> * *damage ("bleomycin-iron"). At the same time lipid peroxidation and
> the
> * *concentration of oxidised ascorbic acid (dehydroascorbate)
> increased
> * *in both serum and synovial fluid, and red-cell glutathione fell.
> These
> * *changes corresponded closely to an exacerbation of rheumatoid
> * *synovitis. Hepatic function was transiently disturbed 7 days after
> the
> * *infusion, reflecting hepatic oxidant stress within the iron-loaded
> * *liver. Such changes provide clear evidence that iron-catalysed
> * *oxidative reactions influence the inflammatory process in human
> beings
>
> * *Major Indexes:
> * * ** Arthritis, Rheumatoid [metabolism]
> * * ** Iron-Dextran Complex [adverse effects]
> * * ** Iron [metabolism]
> * * ** Synovitis [metabolism]
>
> * *Minor Indexes:
> * * ** Bleomycins [diagnostic use]
> * * ** Glutathione [blood]
> * * ** Infusions, Intravenous
> * * ** Iron-Dextran Complex [administration & dosage]
> * * ** Knee Joint [physiopathology]
> * * ** Lipid Peroxides [metabolism]
> * * ** Liver [metabolism]
> * * ** Middle Age
>
> * *Reagent Names:
> * * ** 0 (Bleomycins)
> * * ** 0 (Lipid Peroxides)
> * * ** 70-18-8 (Glutathione)
> * * ** 7439-89-6 (Iron)
> * * ** 9004-66-4 (Iron-Dextran Complex)
>
> Who loves ya.
> Tom
>
> Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh
>
> Man Is A Herbivore!http://tinyurl.com/a3cc3
>
> DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk
>
>
>
> > On May 22, 2:21*pm, "Manky Badger" <you.m...@be.joking> wrote: You
> > don't understand the article <<
>
> > "It is unreliable and the consequences are they give you iron when you
> > have aplastic anemia and you die."
>
> > I think it is you who don't seem to understand a simple sentence.
>
> > How about the part of iron chelation CURES him of his aplastic
> > anemia .. ?
> > It is only a ten sentence article.
> > Are you able to understand .. that .. ?
>
> > The first article is 24 years old.
> > Gave you plenty of time.
> > It is only a ten sentence article.
>
> > You STILL say .. "ferritin is a reliable marker to use" ..
>
> > "It is unreliable and the consequences are they give you iron and you
> > die."
>
> > You should kinda get your sht together seeing you purport to be some
> > kind of pathology .. interested .. guy ..
>
> > Who loves ya.
> > Tom
>
> > Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh
>
> > Man Is A Herbivore!http://tinyurl.com/a3cc3
>
> > DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk
>
> > > "ironjustice" <teamtan...@hotmail.com> wrote in message
>
> > >news:cb427bd0-dee0-46a5-91b3-9d4b1c2e6b5c@25g2000hsx.googlegroups.com....
> > > On May 22, 1:02 am, "Manky Badger" <you.m...@be.joking> wrote: no
> > > stainable iron in the bone marrow, liver, and the heart. *<<
>
> > > The standard test of ferritin does not tell you whether or not you are
> > > iron deficient.
> > > It is unreliable and the consequences are a .. killer.
> > > They give you iron and you die.
>
> > > "Ferritin concentration may not reflect sequestered stores of iron"
> > > __________________________________________________ _________
>
> > > Yes - absolutely. I read that the first time, and now you score another own
> > > goal.
> > > Give up now Tommy - it's like the ESR all over again. You don't understand
> > > the article, and the more you post about it, the more you demonstrate your
> > > lack of understanding.
> > > You were given the chance, and you chose not to take it.- Hide quoted text -
>
> > - Show quoted text -- Hide quoted text -
>
> - Show quoted text - 
Not The Iron 